Biological MArkers of FRAilty in Elderly Subjects (MAFRA)

CHU de Reims

Status: Completed

Conditions: Elderly Persons

Treatments: Other: Blood collection

Study type: Interventional

Funder types: Other

Identifiers

NCT02816580

PO14057

Details and patient eligibility

About

Epidemiological data from Europe have shown that around 30% of subjects aged over 65 years of age are pre-frail, and 15% are frail. Recent research has demonstrated that identifying frailty and implementing preventive measures can help to slow cognitive decline. Screening and treating frailty seem to be a good start towards preventing dependency.

On the premise that this frailty is the result of more pronounced tissue alterations in certain elderly subjects, assessment of post-translational modification derived products (PTMDP) represents an innovative evaluation method. These include advanced glycation end-products (AGE), and carbamylation-derived products (homocitrulline). Indeed, the intensity of these modifications increases with ageing, and assessing the products resulting from these alterations could show the existence of differences according to frailty status. This would make it possible to adapt treatment accordingly in elderly subjects.

Enrollment: 254 patients

Sex: All

Ages: 65+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• With social security coverage
• Accept to participate in the study and sign informed consent for the study and for the collection of biological samples

Exclusion criteria

- < 65 yo

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

254 participants in 1 patient group

elderly subjects

Experimental group

Treatment:

Other: Blood collection